Quantcast
Last updated on April 20, 2014 at 17:20 EDT

Latest Myeloproliferative disease Stories

2011-12-12 16:00:00

- Significant and durable responses in anemia, splenomegaly and constitutional symptoms reported - - Well tolerated for dosing periods up to and exceeding two years - - MRI results confirm meaningful improvements in splenomegaly - MISSISSAUGA, ON, Dec. 12, 2011 /PRNewswire/ - YM BioSciences Inc. (NYSE Amex: YMI, TSX: YM), today reported updated results from the ongoing Phase I/II study of its JAK1/JAK2 inhibitor, CYT387, for the treatment of myelofibrosis. The results are being...

2011-12-12 10:45:00

SINGAPORE, Dec. 12, 2011 /PRNewswire/ -- S*BIO Pte Ltd today announced that results from a Phase 2 study demonstrated that its JAK2 inhibitor pacritinib (SB1518) effectively reduced splenomegaly in myelofibrosis (MF) patients, with minimal impact on existing cytopenias providing an important therapeutic niche in the treatment of MF. Results were presented at the 53rd ASH Annual Meeting and Exposition in San Diego. "Pacritinib is an active drug for the treatment of splenomegaly...

2011-12-12 07:00:00

SAN DIEGO, Dec. 12, 2011 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced data from an oncology pipeline molecule today at the 53rd Annual Meeting of the American Society of Hematology (ASH). At the meeting, Lilly Oncology presented Phase I data from the investigational therapy LY2784544, a small-molecule Janus kinase 2 (JAK2) inhibitor, in development for the treatment of certain types of myeloproliferative neoplasms (MPNs), a group of blood cancers[1] characterized by abnormal...

2011-11-22 07:00:00

SINGAPORE, Nov. 22, 2011 /PRNewswire/ -- S*BIO Pte Ltd today announced that data from Phase 2 studies for its JAK2 inhibitor pacritinib (SB1518) and histone deacetylase inhibitor pracinostat (SB939) demonstrate promising activity in patients with myelofibrosis (MF). Results will be presented at the 53rd ASH Annual Meeting and Exposition in San Diego, Calif. "Pacritinib has been well tolerated and has shown activity in alleviating MF-associated splenomegaly and...

2011-11-07 11:06:00

MISSISSAUGA, ON, Nov. 7, 2011 /PRNewswire/ - YM BioSciences Inc. (NYSE Amex: YMI, TSX: YM), today announced it would report updated results from its Phase I/II myelofibrosis study of CYT387, a JAK1/JAK2 inhibitor, in a poster session to be held from 6:00pm - 8:00pm on Monday, December 12th at the 53rd Annual Meeting of the American Society of Hematology (ASH) being held in San Diego, California. The Company also reported updated results today from the study that were included in an...

2011-11-03 09:51:00

MOUNTAIN VIEW, Calif., Nov. 3, 2011 /PRNewswire/ -- 23andMe, Inc., an industry leader in personal genetics, announced today that Dr. Ruben Mesa has joined its Myeloproliferative Neoplasms (MPN) research project advisory board. In just over two months since its launch, this first-of-its-kind program has already enrolled over 330 individuals with these rare blood cancers in the...

2011-10-25 07:00:00

SINGAPORE, Oct. 25, 2011 /PRNewswire/ -- S*BIO Pte Ltd today announced plans to initiate a global Phase 3 clinical program of its novel JAK2 inhibitor pacritinib (SB1518), in the first half of 2012 to further demonstrate its activity and tolerability for the treatment of myelofibrosis (MF). The company is actively exploring partnering opportunities for the advancement of its leading JAK2 program. "Data from Phase 1 and 2 clinical studies have demonstrated that pacritinib is well...

2011-08-04 08:00:00

- CYT387 suppresses multiple signaling pathways, prevents proliferation and induces apoptosis in myeloma cells - - Results published in July online edition of Leukemia - MISSISSAUGA, ON, Aug. 4, 2011 /PRNewswire/ - YM BioSciences Inc. (NYSE Amex: YMI, TSX: YM), today reported preclinical results for its JAK1/JAK2 inhibitor CYT387 in multiple myeloma (MM), published in the advance online edition of Leukemia on July 26, 2011. The results demonstrate that CYT387 can inhibit MM cellular...

2011-07-18 09:30:00

WHITE PLAINS, N.Y., July 18, 2011 /PRNewswire/ -- The Leukemia & Lymphoma Society (LLS) today announced it has awarded two new Marshall A. Lichtman Specialized Center of Research (SCOR) grants to Frederick W. Alt, Ph.D., Harvard Medical School, and Anthony Green, M.D., Ph.D., University of Cambridge. Each SCOR is valued at $1.25 million a year for five years for a total of $6.25 million. (Logo: http://photos.prnewswire.com/prnh/20110215/NY48642LOGO) The SCOR program is LLS's largest...

2011-06-15 01:00:00

VENLO, The Netherlands, June 15, 2011 /PRNewswire/ -- - QIAGEN in exclusive negotiations to purchase 47% initial stake in Ipsogen S.A.and then fully acquire a global leader in hematologic (blood) cancer molecular diagnostics - Ipsogen has a competitive portfolio in blood cancer testing with assays covering 15 biomarkers-including BCR-ABL and JAK2 -for patient profiling and monitoring - Many of Ipsogen's assays...